Advances in Targeted Cancer Therapy

Abstract

This volume is the first book to cover the general topic of targeted cancer therapy. It presents a range of targets such as tumor angiogenesis, cell cycle control and cell signalling, COX-2, apoptosis/cell survival, invasion and metastasis and approaches like kinase inhibitors, antisense, and antibody-based therapeutics. The emphasis is on preclinical development, including target validation, development of biomarkers, strategies for combination approaches, and development of resistance. The particular challenges involved in translating these data to clinical application are discussed. Dawn of a new era in molecular cancer therapeutics -- Obstacles and opportunities in the clinical development of targeted therapeutics -- Tumor models for preclinical development of targeted agents -- Angiogenesis inhibitors: what is the clinical future? -- Epidermal growth factor receptor (EGFR) inhibitors in cancer therapy -- Cell survival signaling during apoptosis: implications in drug resistance and anti-cancer therapeutic development -- Targeted histone deacetylase inhibition for cancer prevention and therapy -- Inhibitors of cyclin-dependent kinase modulators for cancer therapy -- Targeting cyclooxygenase-2 for cancer prevention and treatment -- Antisense approaches in drug discovery and development -- Preclinical development of Alimta (Pemetrexed LY231514), a multitargeted antifolate.